Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TXG 
10X Genomics Inc (TXG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TXG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15
1 Year Target Price $15
| 5 | Strong Buy |
| 2 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.37% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.54B USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 16 | Beta 2.05 | 52 Weeks Range 6.78 - 18.21 | Updated Date 10/17/2025 |
52 Weeks Range 6.78 - 18.21 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.13% | Operating Margin (TTM) -2.63% |
Management Effectiveness
Return on Assets (TTM) -9.45% | Return on Equity (TTM) -11.3% |
Valuation
Trailing PE - | Forward PE 196.08 | Enterprise Value 1171959085 | Price to Sales(TTM) 2.39 |
Enterprise Value 1171959085 | Price to Sales(TTM) 2.39 | ||
Enterprise Value to Revenue 1.82 | Enterprise Value to EBITDA -40.69 | Shares Outstanding 114411468 | Shares Floating 109327417 |
Shares Outstanding 114411468 | Shares Floating 109327417 | ||
Percent Insiders 1.86 | Percent Institutions 103.58 |
Upturn AI SWOT
10X Genomics Inc
Company Overview
History and Background
10X Genomics was founded in 2012. It focuses on developing and manufacturing instruments and consumables for biological research based on microfluidics. The company has grown rapidly, expanding its product portfolio and market presence through technological advancements and strategic acquisitions.
Core Business Areas
- Genomics: Provides tools for single-cell gene expression analysis, bulk sequencing, and spatial genomics, enabling researchers to understand complex biological systems at high resolution.
- Spatial Biology: Offers platforms for spatially resolved transcriptomics and proteomics, allowing researchers to map gene expression and protein activity within tissues.
- Drug Discovery: Facilitates high-throughput drug screening and target validation, accelerating the drug discovery process.
Leadership and Structure
Serge Saxonov (CEO), Justin Klein (CFO). The company operates with a functional organizational structure, with distinct teams focused on R&D, product development, sales, and marketing.
Top Products and Market Share
Key Offerings
- Chromium: A microfluidics-based platform for single-cell gene expression, ATAC-seq, and CRISPR screening. Holds a significant market share in single-cell genomics. Competitors include Bio-Rad and BD Biosciences. Revenue estimated at $400 million annually.
- Visium: A platform for spatial transcriptomics, enabling researchers to map gene expression within tissue sections. Competitors include NanoString Technologies. Revenue estimated at $100 million annually.
- Xenium: In situ platform providing cellular and sub-cellular spatial resolution, building on 10x's strong brand. Competitors include Akoya Biosciences.
Market Dynamics
Industry Overview
The genomics and spatial biology markets are rapidly growing, driven by increasing demand for high-throughput and high-resolution analysis of biological samples. Technological advancements and decreasing sequencing costs are fueling growth.
Positioning
10X Genomics Inc. is a leading player in the genomics and spatial biology markets, known for its innovative platforms and comprehensive solutions. The company has a strong brand reputation and a large installed base of instruments.
Total Addressable Market (TAM)
The TAM for genomics and spatial biology is estimated to be over $20 billion. 10X Genomics Inc. is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Strong brand reputation
- Large installed base
- Comprehensive solutions
- Strong financial position
Weaknesses
- High product prices
- Reliance on single-cell analysis
- Supply chain vulnerabilities
- Litigation risks
Opportunities
- Expansion into new markets
- Development of new applications
- Strategic partnerships
- Acquisitions of complementary technologies
Threats
- Increasing competition
- Technological obsolescence
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- ILMN
- BIO
- NANO
Competitive Landscape
10X Genomics Inc. faces strong competition from established players and emerging companies in the genomics and spatial biology markets. 10X has an advantage through its superior products but has a disadvantage through the price of its products.
Major Acquisitions
ReadCoor
- Year: 2020
- Acquisition Price (USD millions): 350
- Strategic Rationale: Expanded spatial genomics capabilities.
CartaNA
- Year: 2020
- Acquisition Price (USD millions): 41
- Strategic Rationale: Enhanced in situ analysis capabilities.
Growth Trajectory and Initiatives
Historical Growth: 10X Genomics Inc. has experienced rapid revenue growth over the past five years, driven by increasing adoption of its single-cell and spatial biology platforms.
Future Projections: Analysts project continued revenue growth for 10X Genomics Inc. over the next five years, driven by expansion into new markets and the development of new applications.
Recent Initiatives: Recent initiatives include the launch of new products (Xenium), strategic partnerships, and investments in R&D.
Summary
10X Genomics is a significant player in the rapidly growing genomics market and is known for its innovative technological developments. While it has strong fundamentals and market presence, its profitability remains a concern. Competitors are developing similar technologies which are a threat. Overall, 10X has a strong foothold in the market with room for growth but needs to focus on margin improvement.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 10X Genomics Inc
Exchange NASDAQ | Headquaters Pleasanton, CA, United States | ||
IPO Launch date 2019-09-12 | Co-Founder, CEO & Director Dr. Serge Saxonov Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 1306 | Website https://www.10xgenomics.com |
Full time employees 1306 | Website https://www.10xgenomics.com | ||
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.